News headlines about Rosetta Genomics (NASDAQ:ROSG) have trended somewhat positive this week, according to Accern Sentiment Analysis. The research firm identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Rosetta Genomics earned a news sentiment score of 0.10 on Accern’s scale. Accern also assigned media headlines about the medical research company an impact score of 45.0806771749433 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
A number of brokerages recently weighed in on ROSG. Barrington Research cut shares of Rosetta Genomics from an “outperform” rating to a “market perform” rating in a research note on Monday, December 18th. ValuEngine upgraded shares of Rosetta Genomics from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd.
Rosetta Genomics (NASDAQ:ROSG) traded down $0.01 during mid-day trading on Friday, hitting $0.40. 11,446 shares of the stock traded hands, compared to its average volume of 145,391. Rosetta Genomics has a one year low of $0.23 and a one year high of $5.64. The company has a quick ratio of 2.10, a current ratio of 2.10 and a debt-to-equity ratio of 0.03.
ILLEGAL ACTIVITY WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Rosetta Genomics (ROSG) Stock Price” was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this story on another domain, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The legal version of this story can be accessed at https://www.tickerreport.com/banking-finance/3255894/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-rosetta-genomics-rosg-stock-price.html.
Rosetta Genomics Ltd. is engaged in developing and commercializing new diagnostic tests based on various genomics markers, including deoxyribonucleic acid (DNA), micro ribonucleic acid (microRNA) and protein biomarkers and using various technologies, including, Quantitative polymerase chain reaction (qPCR), microarrays, Next Generation Sequencing (NGS) and Fluorescence In Situ Hybridization (FISH).
Receive News & Ratings for Rosetta Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rosetta Genomics and related companies with MarketBeat.com's FREE daily email newsletter.